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The electronic MEdical Records & GEnomics (eMERGE) network was established in 2007
by the National Human Genome Research Institute (NHGRI) of the National Institutes of
Health (NIH) in part to explore the utility of electronic medical records (EMRs) in genome
science. The initial focus was on discovery primarily using the genome-wide association
paradigm, but more recently, the network has begun evaluating mechanisms to implement
new genomic information coupled to clinical decision support into EMRs. Herein, we
describe this evolution including the development of the individual and merged eMERGE
genomic datasets, the contribution the network has made toward genomic discovery
and human health, and the steps taken toward the next generation genotype-phenotype
association studies and clinical implementation.
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INTRODUCTION
Revolutions in genotyping technology (Ragoussis, 2009) and
computational power coupled with the creation of public sci-
entific resources such as The Human Genome Project (2001;
Venter et al., 2001), The International HapMap Project (2003; The
International HapMap Consortium 2005), and most recently the
1000 Genomes Project (2012), have accelerated genomic discov-
ery, most commonly through genome-wide association studies
(GWAS). As of late March 2014, the National Human Genome
Research Institute (NHGRI) GWAS catalog listed 1201 publica-
tions with 3961 SNPs associated with approximately 571 human
diseases and traits at a significance threshold of 5.0 × 10−8
(Welter et al., 2014) (https://www.genome.gov/26525384)
The majority of genomic discoveries published to date have
been from case-control or cohort epidemiologic studies that
collected specific health-related data and DNA samples. These
traditional epidemiologic collections already exist and are primed
for genomic discovery studies (Willett et al., 2007), mak-
ing them ideal for large-scale GWAS. Also, although currently
under-utilized in genomic discovery, many of the cohorts have
collected exposure data that can be interrogated for gene-
environment interaction studies (Manolio et al., 2006; Thomas,
2010). However, a major disadvantage of accessing existing epi-
demiologic cohorts for genomic discoveries is limited represen-
tation of diverse racial/ethnic groups (Rosenberg et al., 2010) and
of children (Collins andManolio, 2007). Also, the existing health-
related data can be limiting, especially for cohorts or case-controls
collections designed with very specific disease outcomes for study
such as cancers or cardiovascular disease. Finally, establishing and
maintaining an on-going cohort study can pose significant cost
burden (Rukovets, 2013).
The disadvantages of accessing existing case-control and
cohort studies coupled with the continued need for genotype-
phenotype data for genomic discoveries led to the consideration
of alternative study designs and data sources such as bioreposito-
ries linked to electronic medical records (EMRs). In addition for
the potential for large sample sizes of diverse groups, biobanks
linked to EMRs make possible the study of many different out-
comes and traits, many of whichmay not be routinely collected by
traditional epidemiologic cohorts. And, in this burgeoning era of
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precision or personalized medicine, biobanks in clinical settings
offer unprecedented opportunities to quickly translate research
findings to improvements in patient care.
In recognition of the potential for EMR-linked biobanks to
genomic discovery and personalized medicine, NHGRI estab-
lished the electronic MEdical Records & GEnomics (eMERGE)
network. The eMERGE network began in 2007 with a
Coordinating Center (Vanderbilt University) and five study
sites: Group Health/University of Washington, Marshfield Clinic,
Mayo Clinic, Northwestern University, and Vanderbilt University
(McCarty et al., 2011). The network expanded to include new
adult study sites (The Icahn School of Medicine at Mount
Sinai and Geisinger Health System) in 2011 as well as pedi-
atric study sites in 2012 (Children’s Hospital of Philadelphia
and Boston Children’s Hospital/Cincinnati Children’s Hospital
Medical Center) (Gottesman et al., 2013). The major goals of
eMERGE I (McCarty et al., 2011) have evolved with experience,
and the major activities of the Genomics Work Group of the
eMERGE II network are outlined in Figure 1. Here we review
from the perspective of the eMERGE Genomics Work Group
the contributions the network has made toward genomic dis-
covery since 2007. We also foreshadow the eMERGE network’s
contributions to the second generation of genotype-phenotype
associations as well as implementation of genomic medicine.
eMERGE GENOMIC RESOURCES
The first few years of the eMERGE network required data gener-
ation both at the phenotype and genotype levels (McCarty et al.,
2011; Gottesman et al., 2013). In the first phase of the eMERGE
network, each study site proposed an outcome or trait for pheno-
type algorithm development and selection of DNA samples for
genotyping. Since EMR data are generated for the purposes of
clinical care, a necessary step to identifying populations of interest
was to create and validate algorithms that queried data elements
from the EMR to find phenotypes of interest (Kho et al., 2011;
Newton et al., 2013). Typically, these algorithms involved Boolean
combinations of billing codes, medication exposures, laboratory,
and test results, and/or natural language processing. All algo-
rithms and their validation results in the eMERGE network are
available on PheKB (www.phekb.org).
After validation of phenotype algorithms by blinded review,
typically by physicians, matching case, and control samples
were genotyped. All DNA samples were genotyped using either
the Illumina 660-Quad (primarily for participants of European
ancestry) or the Illumina 1M (primarily for participants of
African ancestry) at either the Broad Institute Center for
Genotyping and Analysis or the Center for Inherited Disease
Research (CIDR). The eMERGE Coordinating Center established
a pipeline to process each study site’s data for quality control, data
cleaning, and eventual Database of Genotypes and Phenotypes
(dbGaP) (Mailman et al., 2007) documentation and deposition
(Turner et al., 2011a). The initial round of phenotyping and
genotyping resulted in the generation of GWAS-level data on
19,637 samples, of which 18,663 passed quality control metrics.
The phenotypes and samples sizes available from these eMERGE
phase I efforts included cataracts/HDL-C (2642 cases and 1322
controls; led by Marshfield Clinic), dementia (1241 cases and
2043 controls; led by Group Health Cooperative/University of
Washington), electrocardiographic traits (3034 individuals; led by
Vanderbilt University), peripheral artery disease (1641 cases and
1604; controls led by Mayo Clinic), and type 2 diabetes (2706
cases and 1496 controls; led by Northwestern University).
During phase I of the eMERGE network, high-density geno-
typing had matured such that many large cohorts and biorepos-
itories linked to EMRs had existing GWAS-level data. This
included expanded genotype datasets at some eMERGE I sites
and as such, no new high density genome-wide genotyping was
performed in eMERGE phase II. All existing and new study sites
in eMERGE II offered existing data on a variety of genotyp-
ing platforms and genetic ancestries. With the inclusion of the
eMERGE phase I data, a total of 60,766 (47,507 adult and 13,259
pediatric) samples with GWAS-level genotypes or other large-
scale data [such as Metabochip (Voight et al., 2012)] generated
by either Illumina or Affymetrix arrays are available for study in
eMERGE phase II. As detailed in a separate manuscript (Verma
et al., in press), pooling and merging of these data required impu-
tation and extensive quality control. The current eMERGE phase
II merged dataset (version 2) available for analysis includes 51,038
samples linked to EMRs imputed to >36 million SNPs using the
1000 Genomes Project cosmopolitan reference panel (n = 1092)
and IMPUTE2 (Verma et al., in press).
New to eMERGE phase II is the eMERGE-PGx project, which
involves the targeted sequencing of 84 pharmacogenes identified
by the Pharmacogenomics ResearchNetwork (PGRN) usingDNA
capture and contemporary sequencing technologies (known as
PGRN-Seq) (Rasmussen-Torvik et al., in press). For this effort,
each eMERGE II study site is enrolling ∼1000 patients as a
pilot study of pharmacogenetic sequencing in clinical practice.
Enrollment and sequencing is on-going, and the anticipated
network-wide sample size is 9000. All variants annotated through
this effort will be available in summary data form via the eMERGE
on-line resource “Sequence, Phenotype, and pHarmacogenomics
INtegration eXchange” or “SPHINX” (www.emergesphinx.org).
The eMERGE-PGx project will help establish best practices for
implementing personalized medicine including exploring and
establishing guidelines for returning results to physicians and
patients (Kullo et al., 2014). These data will also contribute toward
the catalog of rare and less common variants and couple them to
EMR data which may increase their clinical utility.
eMERGE GENOMIC DISCOVERIES
It was recognized early in the phenotype and genotype data gen-
eration phase of eMERGE I that large sample sizes are needed
to have sufficient statistical power for genetic association stud-
ies. Indeed, initial GWAS of single eMERGE study site datasets
demonstrated that known genotype-phenotype associations such
as SCN10A and PR duration (Chambers et al., 2010; Holm et al.,
2010; Pfeufer et al., 2010) could be replicated albeit at a signif-
icance threshold above 5.0 × 10−8 (Denny et al., 2010b). While
this exercise of replication demonstrated that EMR-derived phe-
notypes could be used in genotype-phenotype studies, genomic
discovery of new associations would require larger sample sizes.
To achieve this goal, the eMERGE network employed several
strategies, including (1) pooled analysis across the network, (2)
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FIGURE 1 | Major activities of the Genomics Work Group of the eMERGE
network. Abbreviations: CHOP, Children’s Hospital of Philadelphia; CCHMC,
Cincinnati Children’s Hospital Medical Center; BCH, Boston Children’s
Hospital; GHC, Group Health Cooperative; UW, University of Washington;
PSU, Pennsylvania State University; QC, quality control; EMR, electronic
medical record; PheWAS, phenomewide association study; EWAS,
environment-wide association study; CNV, copy number variation; PGx,
pharmacogenomics.
meta-analysis within and with outside consortia, and (3) gen-
eration of new phenotype and genotype data for new studies.
In the first strategy, each eMERGE study site deployed not only
the phenotype used to select study subjects for the genotype-
phenotype association studies of the site’s primary phenotype,
but also the phenotype algorithms designed by other sites to
identify additional cases and controls with existing GWAS-level
genotyping for these secondary phenotypes, This strategy was
successful and identified >15,000 additional samples with exist-
ing GWAS-level data to be repurposed for other phenotypes.
This effort to share and deploy phenotype algorithms across
sites enabled network-wide genomic discoveries for a variety of
quantitative traits (Table 1) and facilitated data sharing for meta-
analysis efforts outside of the eMERGE network for complex
diseases such as late onset Alzheimer’s disease (Naj et al., 2011)
and electrocardiographic traits (Jeff et al., in press).
Implicit in the eMERGE data sharing strategy is the concept
that phenotype algorithms are portable across different study sites
with different EMRs software systems as well as different health
care practices and cultures (Kho et al., 2011). Also, it was assumed
that each study site could reuse data collected for a specific phe-
notype or trait to conduct studies for other unrelated phenotypes
without introducing substantial biases. For example, in the type
2 diabetes (T2D) association study, there was considerable het-
erogeneity in the proportion of type 2 diabetes cases at each site,
as well the odds ratio estimates for the index T2D SNP within
each site’s cohort, but when combined across the sites the odds
ratio was indistinguishable from those using larger purposely-
collected T2D case-control collections (Kho et al., 2012). These
data suggest that potential study heterogeneity was magnified or
measurable at the single study level but dampened at the larger
network-wide level of analysis.
To further test the boundaries of these assumptions and
early observations, eMERGE undertook a network-wide study of
hypothyroidism, a new phenotype not related to any of the study
site-specific phenotypes. The phenotype algorithmwas developed
at the Vanderbilt University study site and deployed and evalu-
ated by all eMERGE study sites, like other eMERGE phenotypes.
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Table 1 | eMERGE and genomic discovery.
Phenotype Nearest gene Genetic effect P Study design Sample References
(rs number) size (Population) size
Alzheimer’s Disease, late
onset
BIN1
(rs7561528)
OR = 1.17
(95% CI: 1.13, 1.22)
4.2 ×10–14 Consortium
meta-analysis, replication
(EA)
8309 cases
7366 controls
Naj et al., 2011
CD2AP
(rs9349407)
OR = 1.11
(95% CI: 1.07, 1.15)
8.6 ×10–9 Consortium
meta-analysis, discovery
+ replication
(EA)
18,762 cases
29,827 controls
CD33
(rs3865444)
OR = 0.91
(95% CI: 0.88, 0.93)
1.6 ×10–9 Consortium
meta-analysis, discovery
+ replication
(EA)
18,762 cases
29,827 controls
CLU
(rs1532278)
OR = 0.89
(95% CI: 0.85, 0.93)
1.9 ×10–8 Consortium
joint-analysis, replication
(EA)
8309 cases
7366 controls
CR1
(rs6701713)
OR = 1.16
(95% CI: 1.11, 1.22)
4.6 ×10–10 Consortium
meta-analysis, replication
(EA)
8309 cases
7366 controls
EPHA1
(rs11767557)
OR = 0.90
(95% CI: 0.86, 0.93)
6.0 ×10–10 Consortium
meta-analysis, discovery
+ replication
(EA)
18,762 cases
35,597 controls
MS4A4A
(rs4938933)
OR = 0.88
(95% CI: 0.85, 0.92)
1.7 ×10–9 Consortium
meta-analysis, discovery
+ replication
(EA)
8309 cases
7366 controls
PICALM
(rs561655)
OR = 0.87
(95% CI: 0.84, 0.91)
7.0 ×10–11 Consortium
meta-analysis, replication
(EA)
8309 cases
7366 controls
Erythrocyte
sedimentation rate
C1orf63
(rs1043879)
β = −0.09 2 ×10–9 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals Kullo et al., 2011
CR1
(rs650877)
β = −0.18 3 ×10–26 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals
CRIL
(rs7527798)
β = 0.10 2 ×10–9 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals
TMEM50A
(rs25547372)
β = −0.10 2. × 10–13 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals
TMEM57
(rs25631242)
β = −0.10 1 ×10–12 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals
TMEM57
(rs25641524)
β = −0.10 5 ×10–13 eMERGE joint analysis,
discovery + replication
(EA)
7607 individuals
HDL-C CETP
(rs3764261)
β = 2.25
(SE = 0.21)
1.22 ×10–25 eMERGE analysis,
replication
(EA)
3740 individuals Turner et al., 2011b
LIPC
(rs11855284)
β = 2.00
(SE = 0.26)
3.92 ×10–14 eMERGE analysis,
replication
(EA)
3740 individuals
(Continued)
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Table 1 | Continued
Phenotype Nearest gene Genetic effect P Study design Sample References
(rs number) size (Population) size
Hypothyroidism FOXE1
(rs7850258)
OR = 0.74
(95% CI: 0.67, 0.82)
3.96 ×10–9 eMERGE joint analysis,
discovery
(EA)
1317 case
5053 controls
Denny et al., 2011
LDL-C APOE
(rs7412)
β = −20.0mg/dl
(95% CI: −25.9,
−14.1)
6.3 ×10–11 eMERGE joint analysis,
discovery
(AA)
618 individuals Rasmussen-Torvik
et al., 2012
Monocyte count CCBP2
(rs2228467)
β = 0.32 2.39 ×10–8 eMERGE joint analysis,
discovery
(EA)
11,014
individuals
Crosslin et al., 2013
IRF8
(rs424971)
β = −0.25 6.32 ×10–18 eMERGE joint analysis,
discovery
(EA)
11,014
individuals
ITGA4
(rs2124440)
β = −0.22 1.35 ×10–14 eMERGE joint analysis,
replication
(EA)
11,014
individuals
RPN1
(rs2712381)
β = −0.22 4.52 ×10–14 eMERGE joint analysis,
replication
(EA)
11,014
individuals
PheWAS EXOC2
(rs12210050)
OR = 1.32
(95% CI: 1.20, 1.45)
1.9 ×10–8 eMERGE pooled
analysis, discovery for
actinic keratosis
(EA)
13,835
individuals
Denny et al., 2013
IRF4
(rs12203592)
OR = 1.69 (95% CI:
1.53, 1.86)
4.1 ×10–26 eMERGE pooled
analysis, discovery for
actinic keratosis
(EA)
13,835
individuals
IRF4
(rs12203592)
OR = 1.50
(95% CI: 1.36, 1.64)
3.8 ×10–17 eMERGE pooled
analysis, discovery for
non-melanoma skin
cancer
(EA)
13,835
individuals
NM37
(rs16861990)
OR = 3.71
(95% CI: 2.57, 5.34)
2.0 ×10–12 eMERGE pooled
analysis, discovery for
hypercoagulable state
(EA)
13,835
individuals
TYR
(rs1847134)
OR = 1.28
(95% CI: 1.18, 1.38)
2.6 ×10–10 eMERGE pooled
analysis, discovery for
non-melanoma skin
cancer
(EA)
13,835
individuals
Platelets ARHGEF3
(rs1354034)
β = −0.19 9.0 ×10–34 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals Shameer et al., 2014
ARHGEF3
(rs1354034)
β = 7.97 6.0 ×10–24 eMERGE pooled
analysis, discovery for
platelet counts
(EA)
13,424
individuals
BET1L
(rs11602954)
β = −6.46 5.0 ×10–12 eMERGE pooled
analysis, discovery for
platelet counts
(EA)
13,424
individuals
(Continued)
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Table 1 | Continued
Phenotype Nearest gene Genetic effect P Study design Sample References
(rs number) size (Population) size
DNM3
(rs2180748)
β = 0.09 2.0 ×10–8 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
FLJ36031-
PIK3CG
(rs342240)
β = −0.15 5.0 ×10–22 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
HBS1L-MYB
(rs4895441)
β = −5.42 9.0 ×10–10 eMERGE pooled
analysis, discovery for
platelet counts
(EA)
13,424
individuals
JMJD1C
(rs4379723)
β = 0.13 3.0 ×10–16 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
NFE2
(rs10506328)
β = −0.09 2.0 ×10–9 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
RCL1
(rs423955)
β = 4.94 1.0 ×10–9 eMERGE pooled
analysis, discovery for
platelet counts
(EA)
13,424
individuals
SH2B3
(rs3184504)
β = −5.33 5.0 ×10–11 eMERGE pooled
analysis, discovery for
platelet counts
(EA)
13,424
individuals
TAOK1
(rs9900280)
β = 0.10 1.0 ×10–10 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
TMCC2
(rs9660992)
β = 0.11 3.0 ×10–13 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
WDR66
(rs7961894)
β = −0.31 6.0 ×10–38 eMERGE pooled
analysis, discovery for
mean platelet volume
(EA)
6291 individuals
QRS duration SCN5a
(rs1805126)
β = −1.0 1.45 ×10–8 eMERGE pooled
analysis, replication
(EA)
5272 individuals Ritchie et al., 2013
Red blood cell traits G6PD
(rs1050828)
β = −0.20
(SE = 0.03)
4.0 ×10–13 eMERGE pooled
analysis, discovery +
replication for RBC count
(AA)
2315 individuals Ding et al., 2013
G6PD
(rs1050828)
β = 2.46
(SE = 0.32)
1.0 ×10–14 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular volume
(AA)
2315 individuals
(Continued)
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Table 1 | Continued
Phenotype Nearest gene Genetic effect P Study design Sample References
(rs number) size (Population) size
G6PD
(rs1050828)
β = 0.72
(SE = 0.12)
9.0 ×10–9 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
(AA)
2315 individuals
ITFG3
(rs9924561)
β = −3.57
(SE = 0.32)
5.0 ×10–29 eMERGE pooled
analysis, discovery +
replication for mean cell
volume
(AA)
2315 individuals
ITFG3
(rs9924561)
β = −1.56
(SE = 0.12)
8.0 ×10–36 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
(AA)
2315 individuals
ITFG3
(rs9924561)
β = −0.47
(SE = 0.06)
4.0 ×10–13 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
concentration
(AA)
2315 individuals
(rs7120391) β = 0.30
(SE = 0.05)
5.0 ×10–9 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
concentration
(AA)
2315 individuals
Red blood cell traits CDT1
(rs837763)
−0.06 2.0 ×10–8 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
concentration
(EA)
12,486
individuals
Ding et al., 2012
PTPLAD1/
C15orf44
(rs8035639)
0.13 8.0 ×10–9 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
(EA)
12,486
individuals
THRB
(rs9310736)
0.35 6.0 ×10–9 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular volume
(EA)
12,486
individuals
(rs9937239) 0.06 2.0 ×10–8 eMERGE pooled
analysis, discovery +
replication for mean
corpuscular hemoglobin
concentration
(EA)
12,486
individuals
Type 2 diabetes TCF7L2
(rs7903146)
OR = 1.41 2.98 ×10–10 eMERGE meta-analysis,
replication
(EA)
2413 cases
2392 controls
Kho et al., 2012
(Continued)
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Table 1 | Continued
Phenotype Nearest gene Genetic effect P Study design Sample References
(rs number) size (Population) size
White blood cell count DARC
(rs12075)
β = 1.28
(SE = 0.12)
4.92 ×10–24 eMERGE joint analysis,
discovery
(AA)
361 individuals Crosslin et al., 2012
White blood cell count GSDMA
(rs3859192)
β = 0.14
(SE = 0.02)
1.75 ×10–12 eMERGE joint analysis,
discovery
(EA)
13,562
individuals
Crosslin et al., 2012
MED24
(rs9916158)
β = −0.13
(SE = 0.02)
4.92 ×10–10 eMERGE joint analysis,
discovery
(EA)
13,562
individuals
PSMD3
(rs4065321)
β = 0.14
(SE = 0.02)
3.47 ×10–11 eMERGE joint analysis,
discovery
(EA)
13,562
individuals
The eMERGE network has conducted or contributed data toward genome-wide association studies. For each study with genome-wide significant results
(p < 5 × 10−8), we list the primary phenotype, the nearest genes associated, the index rs number, the reported genetic effect size, the p-value, the study design,
the population, the sample size, and the reference. Abbreviations: AA, African American; EA, European American; β, beta; CI, confidence interval; OR, odds ratio;
SE, standard error.
Despite potential differences in billing and coding practices across
study sites, a total of 1317 cases and 5053 controls were identi-
fied with average weighted positive predictive values of 92.4 and
98.5, respectively (Denny et al., 2011). The subsequent GWAS
identified common genetic variants near FOXE1 associated with
European American cases, and the findings were replicated in an
independent dataset from the Mayo Genome Consortia as well
as externally in the literature (Eriksson et al., 2012). These stud-
ies illustrate that existing genotype data linked to EMR data can
be reused for other genomic discovery studies, a potentially cost-
effective strategy. However, further study is needed to determine
the extent of biases that were introduced in the generation of these
data that may impact the widespread adoption of this strategy
across a range of phenotypes available in the EMR.
As evident in the FOXE1/hypothyroidism example, existing
genotype data linked to EMR data enable the relatively rapid
identification of cases and controls for traditional GWAS where
one disease or trait is studied. These data have also enabled
the study of pleiotropy, whereby a genetic variant influences or
impacts multiple phenotypes or traits (Stearns, 2010; Solovieff
et al., 2013). In one popular approach, known as phenome-
wide association studies or PheWAS, a GWAS-identified variant
is interrogated for other associations throughout the available
phenome. PheWAS has been performed in both epidemiologic
(Pendergrass et al., 2013a) and EMR-based datasets such as
eMERGE (Denny et al., 2010a, 2013). Collectively, these and other
data (Sivakumaran et al., 2011) suggest that pleiotropy among
GWAS-identified variants is not uncommon. PheWAS con-
ducted in the EMR setting can reveal novel genotype-phenotype
pleiotropic relationships not possible in traditional epidemio-
logic cohorts. For example, a recent PheWAS in the eMERGE
participants of European ancestry revealed a potential associ-
ation between actinic keratosis and IRF4 rs12203592 (Denny
et al., 2013) (Table 1), a GWAS-identified variant previously
associated with hair color, eye color, and non-melanoma skin
cancer (Han et al., 2008; Eriksson et al., 2010; Zhang et al.,
2013).
Much like its contributions toward the study of pleiotropy,
the eMERGE network is beginning to make substantial contribu-
tions to understudied or burgeoning areas of interest in genomic
discovery such as the study of pediatric populations and diverse
racial/ethnic groups. Indeed, with the addition of the pediatric
study sites, eMERGE II boasts one of the largest collections of
pediatric DNA samples linked to EMRs for genomic discovery
(Gottesman et al., 2013). The current version (2) of the merged,
imputed eMERGE II dataset includes >12,000 pediatric samples
linked to EMRs. As of March 15, 2014, fewer than 5% of the
GWAS annotated by the NHGRI GWAS Catalog (Welter et al.,
2014) mention children as a study population, highlighting the
tremendous opportunity for genomic discovery in this cohort.
To calibrate the eMERGE II datasets, a site-specific investigation
was recently performed for body mass index (BMI) z-scores using
BMI extracted from the pediatric EMRs and calculated using
the Centers for Disease Control and Prevention (CDC) growth
charts (Namjou et al., 2013). Similar to epidemiologic datasets
(Frayling et al., 2007; Meyre et al., 2009; Scherag et al., 2010), this
EMR-based study demonstrated that adult GWAS-identified obe-
sity variants such as those in FTO were also relevant for children
of European-descent (Namjou et al., 2013). Genomic discovery
using GWAS in pediatric populations is currently underway in
eMERGE II for complex phenotypes such as autism and asthma.
In the past several years, most GWAS have included indi-
viduals of European ancestry (Rosenberg et al., 2010). Indeed,
only approximately 10% of the GWAS annotated in the NHGRI
GWAS Catalog include populations of African ancestry (https://
www.genome.gov/26525384). The eMERGE network is signifi-
cantly poised to contribute to GWA studies for populations of
non-European ancestry given that several study sites (notably
Northwestern University, Vanderbilt University, and The Icahn
School of Medicine at Mount Sinai) include participants of
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African ancestry. eMERGE I has already contributed genome-
wide associated variants (at a threshold of p < 10−5) in par-
ticipants of African ancestry to the NHGRI GWAS Catalog for
LDL-C (Rasmussen-Torvik et al., 2012), red blood cell traits
(Ding et al., 2013), white blood cell traits (Crosslin et al., 2012),
type 2 diabetes (Kho et al., 2012), and electrocardiographic traits
(Jeff et al., 2013). As an extension of GWAS, eMERGE investiga-
tors have also begun fine-mapping GWAS-identified regions to
identify the best index variant in African ancestry populations as
well as exploring alternative genomic discovery methods such as
admixture mapping to identify potentially novel or population-
specific associations (Jeff et al., 2014).
Beyond conventional GWAS, the eMERGE network has also
led efforts to identify genetic (G×G) and environmental (G× E)
modifiers of common, complex phenotypes. In an early example,
eMERGE investigators used extrinsic biological knowledge via the
Biofilter algorithm (Bush et al., 2009) to prioritize genetic vari-
ants for SNP-SNP modeling to identify gene-gene interactions
relevant for HDL-C (Turner et al., 2011b). The extrinsic biolog-
ical knowledge approach has also been recently implemented for
both G × G and G × E tests of association for cataracts, with the
latter including only environmental variables known to be asso-
ciated with the eye disease (Pendergrass et al., 2013b,c). Finally,
eMERGE investigators have implemented environmental-wide
association studies (EWAS) to identify and prioritize environ-
mental factors important for type 2 diabetes (Hall et al., 2014),
a relatively new approach to identify all possible environmental
variables that may be relevant for G × E studies for the disease of
interest.
eMERGE SECOND GENERATION GWAS
The majority of GWAS described to date for the eMERGE net-
work represent data and efforts from phase I of the network’s
existence. Phase II analyses of larger, more diverse sample sizes are
on-going (Gottesman et al., 2013). As documented and described
in an accompanying article (Verma et al., in press), eMERGE
II network datasets include single site datasets, a network-
wide merged genotyped dataset, single site imputed datasets,
and a network-wide merged imputed dataset; the merged set
includes >36 million SNPs for samples from >50,000 indi-
viduals linked to EMRs. Imputation of the X-chromosome is
underway, and future eMERGE II analyses will include this
chromosome. Network-wide efforts are also underway to anno-
tate copy number variants (Connolly et al., 2014) as well as
to annotate and identify potentially deleterious null variants.
Site-specific efforts are also underway to collect or extract addi-
tional standardized environmental data for GxE studies using
the PhenX Toolkit (Hamilton et al., 2011; McCarty et al.,
2014). Efforts are underway to develop analytical approaches
for repeated measures data characteristic of the EMR, to con-
duct mapping studies for populations with three-way admixture
events, and to incorporate phenotyping uncertainty when bal-
ancing sample size/power and misclassification (McDavid et al.,
2013). With >36 million SNPs, large sample sizes, and phe-
notypically dense EMRs, eMERGE II and beyond promises
to continue genomic discovery in the second generation of
GWAS.
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